Sanofi outlays $1.9bn to purchase Dren Bio’s bispecific antibody
Sanofi’s move for Dren Bio’s clinical asset boosts its immunology-focused strategy of becoming a leader in the field.
Sanofi’s move for Dren Bio’s clinical asset boosts its immunology-focused strategy of becoming a leader in the field.
What's Your Reaction?
